{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:24:01Z","timestamp":1779207841743,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>Amid a reappraisal of the medicinal and societal worth of psychedelics in many countries, regulatory and financial barriers to conducting clinical research with these compounds appear to be receding. Still, there remains a strong need for a clearer understanding of naturalistic psychedelic use and its associated epidemiology, since this type of psychedelic use, which is growing in many places, will almost certainly always exceed clinical use. Furthermore, psychedelics behave differently depending on the settings in which they are used, meaning many research findings on their effects may significantly differ depending on the contexts in which they are observed. Therefore, improving the collection of data on real-world psychedelic use should be of higher priority for the public health community. Expanding data collection on psychedelic use in the United States National Survey on Drug Use and Health, an already vital tool for researchers examining naturalistic psychedelic use, could address this important public health need, helping ensure the general public, the scientific community, and regulators have access to high-quality information as peoples across the world reevaluate what psychedelics\u2019 place in medicine and society should be.<\/jats:p>","DOI":"10.1177\/02698811221123051","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T07:02:16Z","timestamp":1663311736000},"page":"1097-1099","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8963-5701","authenticated-orcid":false,"given":"Brian S","family":"Barnett","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA"},{"name":"Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103473"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0018246X21000224."},{"key":"e_1_3_2_4_1","unstructured":"British Broadcasting Corporation (2022) Canada trials decriminalising cocaine MDMA and other drugs. BBC News 1 June. London: British Broadcasting Corporation. Available at: https:\/\/www.bbc.com\/news\/world-us-canada-61657095 (accessed 2 June 2022)."},{"key":"e_1_3_2_5_1","unstructured":"Campbell D (2022) Demand grows for UK ministers to reclassify psilocybin for medical research. The Guardian 7 March. London: Guardian Media Group. Available at: https:\/\/www.theguardian.com\/science\/2022\/mar\/08\/demand-grows-for-uk-ministers-to-reclassify-psilocybin-for-medical-research (accessed 2 June 2022)."},{"key":"e_1_3_2_6_1","unstructured":"Global Drug Survey (2022) Survey composition. Available at: https:\/\/www.globaldrugsurvey.com\/gds-surveys\/survey-composition\/ (accessed 2 June 2022)."},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.2307\/981310."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15789."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050324516683325"},{"key":"e_1_3_2_10_1","unstructured":"Johns Hopkins Medicine (2021) Johns hopkins medicine receives first federal grant for psychedelic treatment research in 50 years. Available at: https:\/\/www.hopkinsmedicine.org\/news\/newsroom\/news-releases\/johns-hopkins-medicine-receives-first-federal-grant-for-psychedelic-treatment-research-in-50-years#:~:text=in 50years- Johns Hopkins Medicine Receives First Federal Grant Treatment Research in 5 (accessed 3 June 2022)."},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06580-2."},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211058923."},{"key":"e_1_3_2_13_1","unstructured":"Kamin D (2021) The rise of psychedelic retreats. New York Times 25 November. New York NY: The New York Times Company. Available at: https:\/\/www.nytimes.com\/2021\/11\/25\/travel\/psychedelic-retreat-ayahuasca.html (accessed 2 June 2022)."},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306486."},{"key":"e_1_3_2_15_1","unstructured":"Ponieman N (2021) Are psychedelics legal in the US? Where are they decriminalized? A deep dive into the legal status of psilocybin MDMA LSD ketamine and more. Available at: https:\/\/www.yahoo.com\/video\/psychedelics-legal-us-where-decriminalized-155555653.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAKyCfAKCh8MXimizun0p0ZYsAl56VJynInaZc_XwIBbalNryGyqPkk17kkd8ZAyxE7VkKsMiLjwBPa6qgXQhpfE_ (accessed 4 June 2022)."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010035."},{"key":"e_1_3_2_17_1","unstructured":"Substance Abuse and Mental Health Data Archive (2020) National Survey on Drug Use and Health (NSDUH) 2020 population data. Available at: https:\/\/www.datafiles.samhsa.gov\/dataset\/national-survey-drug-use-and-health-2020-nsduh-2020-ds0001 (accessed 17 February 2022)."},{"key":"e_1_3_2_18_1","unstructured":"Substance Abuse and Mental Health Services Administration (2021) 2020 National Survey on Drug Use and Health Public Use File Codebook. Rockville MD: Substance Abuse and Mental Health Services Administration. Available at: https:\/\/www.datafiles.samhsa.gov\/sites\/default\/files\/field-uploads-protected\/studies\/NSDUH-2020\/NSDUH-2020-datasets\/NSDUH-2020-DS0001\/NSDUH-2020-DS0001-info\/NSDUH-2020-DS0001-info-codebook.pdf (accessed 2 June 2022)."},{"key":"e_1_3_2_19_1","unstructured":"United Kingdom Government (2021) United Kingdom Drug Situation 2019: Focal Point Annual Report. Available at: https:\/\/www.gov.uk\/government\/publications\/united-kingdom-drug-situation-focal-point-annual-report\/united-kingdom-drug-situation-focal-point-annual-report-2019#ketamine (accessed 4 June 2022)."},{"key":"e_1_3_2_20_1","first-page":"684","article-title":"Epidemiology of hallucinogenic drug use in the Netherlands","volume":"62","author":"van Laar MW","year":"2020","unstructured":"van Laar MW, van Miltenburg CJA (2020) Epidemiology of hallucinogenic drug use in the Netherlands. Tijdschr Psychiatr 62: 684\u2013692.","journal-title":"Tijdschr Psychiatr"},{"key":"e_1_3_2_21_1","unstructured":"Winstock A Timmerman C Davies E et al. (2020) Global Drug Survey (GDS) 2020 Psychedelics Key Findings Report. London: Global Drug Survey. Available at: https:\/\/www.globaldrugsurvey.com\/wp-content\/uploads\/2021\/03\/GDS2020-Psychedelics-report.pdf (accessed 2 June 2022)."},{"key":"e_1_3_2_22_1","unstructured":"Winstock A Maier L Zhuparris A et al. (2021) Global Drug Survey (GDS) 2021 Key Findings Report. London: Global Drug Survey. Available at: https:\/\/www.globaldrugsurvey.com\/wp-content\/uploads\/2021\/12\/Report2021_global.pdf (accessed 2 June 2022)."},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2020.00159."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108071."}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811221123051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811221123051","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811221123051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:09Z","timestamp":1777507869000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811221123051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/02698811221123051"],"URL":"https:\/\/doi.org\/10.1177\/02698811221123051","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]}}}